ReviewPharmaceutical science advances2026
From barrier to guide: Exploiting disease-specific hemodynamics for enhanced nanodrug targeting in cardiovascular diseases.
Review in Pharmaceutical science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular diseases (CVDs) remain the leading cause of global mortality. Conventional systemic drug administration is plagued by issues such as suboptimal bioavailability and off-target effects. As an emerging vehicle, nanoparticles offer the potential to enhance therapeutic efficacy and reduce side effects through their targeted delivery properties. The hemodynamic characteristics under pathological conditions directly determine the success of targeted delivery by regulating the distribution, retention, and extravasation of nanoparticles within the circulation. This review systematically summarizes the pathological characteristics and disease-specific hemodynamic features of common CVDs: atherosclerosis, aneurysms, phlebitis, and venous thromboembolism. It thoroughly examines their critical influence on the delivery behavior of nanoparticles in blood and summarizes three targeted delivery strategies: passive targeting achieved by regulating nanocarrier properties, active targeting realized through the design of stimuli-responsive carriers, and homing effects attained via biomimetic modifications. Additionally, it summarizes relevant computational, experimental, and in vivo imaging methodologies for simulating blood flow dynamics and monitoring nanocarrier behavior. This review aims to provide a systematic perspective for understanding the role of hemodynamics in targeted delivery of nanomedicines, and to offer theoretical foundations and research paradigms for designing more efficient and lesion-selective cardiovascular nano-delivery systems.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.